AtaiBeckley Inc. (NASDAQ:ATAI) is one of Best Stocks Under $5 With Huge Upside Potential. Guggenheim raised the price target on AtaiBeckley Inc. (NASDAQ:ATAI) to $16 from $11 on April 17, maintaining a Buy rating on the stock. The company told investors that its recent meetings with management reinforced its “conviction” in the BPL-003 program ahead of the start of Phase 3 this quarter.
In another development, AtaiBeckley Inc. (NASDAQ:ATAI) announced peer-reviewed Phase 2a results on April 8 in medications for the central nervous system, demonstrating that a single intranasal dose of BPL-003 achieved rapid and sustained reductions in MADRS scores from baseline in participants with treatment-resistant depression who remained on stable SSRI therapy throughout the study. BPL-003 holds FDA Breakthrough Therapy Designation.
Management reported that a 66.7% antidepressant response rate was observed at day 2 in both the 10 mg (n=6) and 12 mg (n=6) cohorts, with 83% of participants in the 10 mg cohort and 66.7% of participants in the 12 mg cohort maintaining a response at week 12.
Headquartered in Germany, AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on the treatment of mental health disorders.
While we recognize ATAI’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 15 stocks that will make you rich in 10 years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.